A Phase II Trial of Buparlisib in Patients with Platinum-Resistant Metastatic Urothelial Carcinoma

A Phase II Trial of Buparlisib in Patients with Platinum-Resistant Metastatic Urothelial Carcinoma

PI3K pathway inhibition with buparlisib exhibited modest activity in metastatic urothelial carcinoma with significant toxicity. Further studies of PI3K pathway inhibition should focus on patients with select genetic alterations and using isoform-selective inhibitors.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2020-08, Vol.126 (20), p.4532-4544
Hauptverfasser: McPherson, Victor, Reardon, Brendan, Bhayankara, Aravind, Scott, Sasinya N., Boyd, Mariel E., Garcia-Grossman, Ilana R., Regazzi, Ashley M., McCoy, Asia S., Kim, Philip H., Al-Ahmadie, Hikmat, Ostrovnaya, Irina, Roth, Andrew J., Farooki, Azeez, Berger, Michael F., Rosenberg, Jonathan E., Solit, David B., Van Allen, Eliezer, Milowsky, Matthew I, Bajorin, Dean F., Iyer, Gopa
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PI3K pathway inhibition with buparlisib exhibited modest activity in metastatic urothelial carcinoma with significant toxicity. Further studies of PI3K pathway inhibition should focus on patients with select genetic alterations and using isoform-selective inhibitors.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33071